Xu ZQ, Kang YK, Zhang J et al. NIR-triggered on-site NO/ROS/RNS nanoreactor: Cascade-amplified photodynamic/photothermal therapy with local and systemic immune responses activation. Opto-Electron Adv 7, 240013 (2024). doi: 10.29026/oea.2024.240013
Citation: Xu ZQ, Kang YK, Zhang J et al. NIR-triggered on-site NO/ROS/RNS nanoreactor: Cascade-amplified photodynamic/photothermal therapy with local and systemic immune responses activation. Opto-Electron Adv 7, 240013 (2024). doi: 10.29026/oea.2024.240013

Article Open Access

NIR-triggered on-site NO/ROS/RNS nanoreactor: Cascade-amplified photodynamic/photothermal therapy with local and systemic immune responses activation

More Information
  • Photothermal and photodynamic therapies (PTT/PDT) hold promise for localized tumor treatment, yet their full potential is hampered by limitations such as the hypoxic tumor microenvironment and inadequate systemic immune activation. Addressing these challenges, we present a novel near-infrared (NIR)-triggered RNS nanoreactor (PBNO-Ce6) to amplify the photodynamic and photothermal therapy efficacy against triple-negative breast cancer (TNBC). The designed PBNO-Ce6 combines sodium nitroprusside-doped Prussian Blue nanoparticles with Chlorin e6 to enable on-site RNS production through NIR-induced concurrent NO release and ROS generation. This not only enhances tumor cell eradication but also potentiates local and systemic antitumor immune responses, protecting mice from tumor rechallenge. Our in vivo evaluations revealed that treatment with PBNO-Ce6 leads to a remarkable 2.7-fold increase in cytotoxic T lymphocytes and a 62% decrease in regulatory T cells in comparison to the control PB-Ce6 (Prussian Blue nanoparticles loaded with Chlorin e6), marking a substantial improvement over traditional PTT/PDT. As such, the PBNO-Ce6 nanoreactor represents a transformative approach for improving outcomes in TNBC and potentially other malignancies affected by similar barriers.
  • 加载中
  • [1] Overchuk M, Weersink RA, Wilson BC et al. Photodynamic and photothermal therapies: synergy opportunities for nanomedicine. ACS Nano 17, 7979–8003 (2023). doi: 10.1021/acsnano.3c00891

    CrossRef Google Scholar

    [2] Shen S, Qiu JC, Huo D et al. Nanomaterial-enabled photothermal heating and its use for cancer therapy via localized hyperthermia. Small 20, 2305426 (2024). doi: 10.1002/smll.202305426

    CrossRef Google Scholar

    [3] Yang HY, Liu RF, Xu YX et al. Photosensitizer nanoparticles boost photodynamic therapy for pancreatic cancer treatment. Nanomicro Lett 13, 35 (2021).

    Google Scholar

    [4] Hu TT, Wang ZD, Shen WC et al. Recent advances in innovative strategies for enhanced cancer photodynamic therapy. Theranostics 11, 3278–3300 (2021). doi: 10.7150/thno.54227

    CrossRef Google Scholar

    [5] Lee D, Kwon S, Jang SY et al. Overcoming the obstacles of current photodynamic therapy in tumors using nanoparticles. Bioact Mater 8, 20–34 (2022).

    Google Scholar

    [6] Yuan C, Li Y, Xu ZQ et al. Imaging-guided synergistic photo-chemotherapy using doxorubicin-loaded gadolinium porphyrin-based metal-organic framework nanosheets. ACS Appl Nano Mater 5, 15318–15327 (2022). doi: 10.1021/acsanm.2c03390

    CrossRef Google Scholar

    [7] Wang SJ, Huang P, Nie LM et al. Single continuous wave laser induced photodynamic/plasmonic photothermal therapy using photosensitizer-functionalized gold nanostars. Adv Mater 25, 3055–3061 (2013). doi: 10.1002/adma.201204623

    CrossRef Google Scholar

    [8] Yang S, Sun B, Liu F et al. NIR-II imaging-guided mitochondrial-targeting organic nanoparticles for multimodal synergistic tumor therapy. Small 19, 2207995 (2023). doi: 10.1002/smll.202207995

    CrossRef Google Scholar

    [9] Yue J, Mei Q, Wang PY et al. Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy. J Nanobiotechnol 20, 181 (2022). doi: 10.1186/s12951-022-01388-8

    CrossRef Google Scholar

    [10] Li ZL, Lai XQ, Fu SQ et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci (Weinh) 9, 2201734 (2022). doi: 10.1002/advs.202201734

    CrossRef Google Scholar

    [11] Wang MY, He MY, Zhang MY et al. Controllable hypoxia-activated chemotherapy as a dual enhancer for synergistic cancer photodynamic immunotherapy. Biomaterials 301, 122257 (2023). doi: 10.1016/j.biomaterials.2023.122257

    CrossRef Google Scholar

    [12] Zhao M, Zhang YY, Miao J et al. An activatable phototheranostic probe for anti-hypoxic type i photodynamic- and immuno-therapy of cancer. Adv Mater 36, 2305243 (2024). doi: 10.1002/adma.202305243

    CrossRef Google Scholar

    [13] Yun HY, Dawson VL, Dawson TM. Nitric oxide in health and disease of the nervous system. Mol Psychiatry 2, 300–310 (1997). doi: 10.1038/sj.mp.4000272

    CrossRef Google Scholar

    [14] Marletta MA. Nitric oxide: biosynthesis and biological significance. Trends Biochem Sci 14, 488–492 (1989). doi: 10.1016/0968-0004(89)90181-3

    CrossRef Google Scholar

    [15] Chang MY, Wang M, Liu YH et al. Dendritic plasmonic CuPt alloys for closed-loop multimode cancer therapy with remarkably enhanced efficacy. Small 19, 2206423 (2023). doi: 10.1002/smll.202206423

    CrossRef Google Scholar

    [16] Chen Y, Li ZH, Pan P et al. Tumor-specific ONOO nanogenerator for improved drug delivery and enhanced chemotherapy of tumor. ACS Nano 15, 11514–11525 (2021). doi: 10.1021/acsnano.1c01312

    CrossRef Google Scholar

    [17] Shi MH, Zhang JL, Wang Y et al. Tumor-specific nitric oxide generator to amplify peroxynitrite based on highly penetrable nanoparticles for metastasis inhibition and enhanced cancer therapy. Biomaterials 283, 121448 (2022). doi: 10.1016/j.biomaterials.2022.121448

    CrossRef Google Scholar

    [18] Ji CW, Si JX, Xu Y et al. Mitochondria-targeted and ultrasound-responsive nanoparticles for oxygen and nitric oxide codelivery to reverse immunosuppression and enhance sonodynamic therapy for immune activation. Theranostics 11, 8587–8604 (2021). doi: 10.7150/thno.62572

    CrossRef Google Scholar

    [19] Beurton J, Boudier A, Barozzi Seabra A et al. Nitric oxide delivering surfaces: an overview of functionalization strategies and efficiency progress. Adv Healthc Mater 11, 2102692 (2022). doi: 10.1002/adhm.202102692

    CrossRef Google Scholar

    [20] van der Vlies AJ, Yamane S, Hasegawa U. Recent advance in self-assembled polymeric nanomedicines for gaseous signaling molecule delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 16, e1934 (2024). doi: 10.1002/wnan.1934

    CrossRef Google Scholar

    [21] Gao D, Asghar S, Hu RF et al. Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy. Acta Pharm Sin B 13, 1498–1521 (2023). doi: 10.1016/j.apsb.2022.11.016

    CrossRef Google Scholar

    [22] Tavakkoli Yaraki M, Liu B, Tan YN. Emerging strategies in enhancing singlet oxygen generation of nano-photosensitizers toward advanced phototherapy. Nanomicro Lett 14, 123 (2022).

    Google Scholar

    [23] So JY, Ohm J, Lipkowitz S et al. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther 237, 108253 (2022). doi: 10.1016/j.pharmthera.2022.108253

    CrossRef Google Scholar

    [24] Jia HY, Truica CI, Wang B et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat 32, 1–15 (2017). doi: 10.1016/j.drup.2017.07.002

    CrossRef Google Scholar

    [25] Chen X, Iliopoulos D, Zhang Q et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature 508, 103–107 (2014). doi: 10.1038/nature13119

    CrossRef Google Scholar

    [26] Ding MC, Shao K, Wu LJ et al. A NO/ROS/RNS cascaded-releasing nano-platform for gas/PDT/PTT/immunotherapy of tumors. Biomater Sci 9, 5824–5840 (2021). doi: 10.1039/D1BM00726B

    CrossRef Google Scholar

    [27] Ma SJ, Zhao Y, Lee WC et al. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nat Commun 13, 4118 (2022). doi: 10.1038/s41467-022-31764-9

    CrossRef Google Scholar

    [28] Thomas AA, Fisher JL, Rahme GJ et al. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol 17, 801–809 (2015). doi: 10.1093/neuonc/nou363

    CrossRef Google Scholar

    [29] Zhang J, Xu ZQ, Li Y et al. Theranostic mesoporous platinum nanoplatform delivers halofuginone to remodel extracellular matrix of breast cancer without systematic toxicity. Bioeng Transl Med 8, e10427 (2023). doi: 10.1002/btm2.10427

    CrossRef Google Scholar

    [30] Gotwals P, Cameron S, Cipolletta D et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer 17, 286–301 (2017). doi: 10.1038/nrc.2017.17

    CrossRef Google Scholar

    [31] Racle J, de Jonge K, Baumgaertner P et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife 6, e26476 (2017). doi: 10.7554/eLife.26476

    CrossRef Google Scholar

    [32] Feng T, Wan JY, Li P et al. A novel NIR-controlled NO release of sodium nitroprusside-doped Prussian blue nanoparticle for synergistic tumor treatment. Biomaterials 214, 119213 (2019). doi: 10.1016/j.biomaterials.2019.05.024

    CrossRef Google Scholar

    [33] Wang SJ, Ma XQ, Hong XH et al. Adjuvant photothermal therapy inhibits local recurrences after breast-conserving surgery with little skin damage. ACS Nano 12, 662–670 (2018). doi: 10.1021/acsnano.7b07757

    CrossRef Google Scholar

    [34] Tallarida RJ. Quantitative methods for assessing drug synergism. Genes Cancer 2, 1003–1008 (2011). doi: 10.1177/1947601912440575

    CrossRef Google Scholar

    [35] Wu QH, You L, Nepovimova E et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol 15, 77 (2022). doi: 10.1186/s13045-022-01292-6

    CrossRef Google Scholar

    [36] Wei HM, Xu ZM, Chen LC et al. Long non-coding RNA PAARH promotes hepatocellular carcinoma progression and angiogenesis via upregulating HOTTIP and activating HIF-1α/VEGF signaling. Cell Death Dis 13, 102 (2022). doi: 10.1038/s41419-022-04505-5

    CrossRef Google Scholar

    [37] Hoskin PJ, Sibtain A, Daley FM et al. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89, 1290–1297 (2003). doi: 10.1038/sj.bjc.6601260

    CrossRef Google Scholar

    [38] Lynch MS, Cheng M, Van Kuiken BE et al. Probing the photoinduced metal-nitrosyl linkage isomerism of sodium nitroprusside in solution using transient infrared spectroscopy. J Am Chem Soc 133, 5255–5262 (2011). doi: 10.1021/ja110881n

    CrossRef Google Scholar

  • Supplementary information for NIR-triggered on-site NO/ROS/RNS nanoreactor: Cascade-amplified photodynamic/photothermal therapy with local and systemic immune responses activation
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Figures(8)

Article Metrics

Article views(849) PDF downloads(298) Cited by(0)

Access History
Article Contents

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint